Anthony Fauci, April 29, 2020: "The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery," Fauci said during a meeting with President Trump and Louisiana Gov. John Bel Edwards. "This is highly significant."
Try Dr. Brian Ardis. In my little world,he’s who brought the Ebola trials to the open. He looked at all of those trials and screamed it out to the world. He may have done a deeper dive into the 2009 trials if available at the time, and if he found. Remdesivir was given to his father in law.
Citations below refer to the HCV trials.
I have no more time now to continue but suspect such information will only be found as part of some other reference and maybe some supplemental material that has been ignored.
Cihlar, T., & Mackman, R. L. (2022). Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antiviral Therapy, 27(2), 13596535221082773.
Gammeltoft, K. A., Zhou, Y., Duarte Hernandez, C. R., Galli, A., Offersgaard, A., Costa, R., ... & Gottwein, J. M. (2021). Hepatitis C virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in vitro. Antimicrobial Agents and Chemotherapy, 65(9), e02680-20.
TALK TO GEORGE WEBB🥸 https://twitter.com/RealGeorgeWebb1/status/1649479442324922368?s=20
Remdesivir and hospital protocol killed my husband .
I don’t have a link.. but read that 3 drugs were involved in the Ebola trial. Remdesivir was one of them & had to be withdrawn bec it caused multi organ failure & death in around 54% of the non placebo group. It was removed from the trial & shelved.
The Phase 1b clinical trial of remdesivir in combination with pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection was conducted by Gilead Sciences. The authors of the publication reporting the results of this trial in the New England Journal of Medicine were:
Robert R. Redfield, MD
Jeffrey A. Allegaert, MD
Hongmei Huang, PhD
Yaming Wang, PhD
Jeanne M. Buxton, PharmD
Jinsheng Yu, PhD
Dong Xu, PhD
Kristina H. Watt, PhD
Janet E. Gounder, MD
G. Mani Subramanian, MD
George M. Shaw, MD, PhD
John G. McHutchison, MD
Calvin J. Cohen, MD, MPH
Andrew J. Muir, MD
Raymond F. Schinazi, PhD
J. Michael Kilby, MD
This publication, entitled "Assessment of Hepatitis C Virus RNA Levels in Nonclinical Studies and Early Clinical Trials of Remdesivir, a Direct-Acting Antiviral Agent," was published in the New England Journal of Medicine in May 2012.
The article was titled "A Randomized Study of the Safety and Antiviral Activity of Various Combination Doses of Sofosbuvir (GS-7977) and Ribavirin in HCV-Infected Subjects With Inadequate Response to Standard of Care: The ATOMIC Study" and was published in the May 17, 2012 issue of the New England Journal of Medicine. This article reported the results of a study that evaluated the safety and efficacy of the combination of sofosbuvir (another HCV treatment) and ribavirin in HCV-infected patients who had previously failed standard-of-care therapy.
The Phase 1b trial of remdesivir in combination with pegylated interferon and ribavirin for the treatment of chronic HCV infection was also published in the May 17, 2012 issue of the New England Journal of Medicine, in an article titled "Remdesivir and Interferon-α with or without Ribavirin for HCV Infection."
The Phase 1b clinical trial of remdesivir for the treatment of chronic hepatitis C virus (HCV) infection, which was published in the New England Journal of Medicine in 2012, reported that the combination of remdesivir and interferon-α with or without ribavirin was generally safe and well-tolerated in the study population.
The study enrolled 36 patients with chronic HCV infection who received either remdesivir and interferon-α, or remdesivir, interferon-α, and ribavirin for 28 days. The most commonly reported adverse events were fatigue, headache, nausea, and myalgia, which are also common side effects of interferon-based therapies.
Overall, the combination of remdesivir and interferon-α with or without ribavirin did not result in any serious adverse events, and none of the patients discontinued treatment due to adverse events. The authors of the study concluded that the combination of remdesivir and interferon-α with or without ribavirin showed potential for further clinical development as a treatment for chronic HCV infection.
GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients.
GS-441524 (metabolite of prodrug Remdesivir) without the 2′-β-C-Me was synthesized in 2009 as a relatively less potent inhibitor of HCV and thus was not pursued further for this indication.
Its predecessors (similar to but not Remdesivir) failed in clinical trials due to safety concerns.
Remdesivir apparently did not enter clinical trials because it was clear that while it may or may not have been safer, it would not be effective against Hep C and so they pursued another drug which got approved
Fauci said at one point, the next administration/Trump, would be faced with a 'surprise outbreak'. They knew full well what was going to happen and Fauci knew what Remdesivir would do to people with the right cocktail of drugs. It creates a perfect storm in the human body. Fauci may be the top rat, but a whole host of people including the doctors & nurses are complicit. I agree with you, no one will do it for us.
Did you FOIL for the documents? You have information to do it.
Excellent point about how to use lawyers to get the justice you need - pay as you go.